Trial Profile
Pharmacokinetics of BC-3781 in the pulmonary epithelial lining fluid, skeletal muscle tissue, subcutaneous adipose tissue and in plasma of Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2019
Price :
$35
*
At a glance
- Drugs Lefamulin (Primary)
- Indications Bacterial infections; Bone and joint infections; Community-acquired pneumonia; Nosocomial pneumonia; Osteomyelitis; Sexually transmitted infections; Skin and soft tissue infections
- Focus Pharmacokinetics
- Sponsors Nabriva Therapeutics
- 01 Apr 2019 Results of population PK model to predict the ELF penetration ratio of lefamulin after IV or oral administration in the fed and fasted state using data from NAB-BC3781-1107 and NAB-BC3781-1005 studies, published in the Journal of Antimicrobial Chemotherapy
- 07 Jan 2016 Results published in the Journal of Antimicrobial Chemotherapy
- 16 Sep 2014 New trial record